Ahsan Usmani

Mr. Ahsan Usmani

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2022 in Cells
Verified
Journal Article
Open access
PDF file
BBBeverly Brooks
Beverly Brooks
DEDominique Ebedes
Dominique Ebedes
AUAhsan Usmani
Ahsan Usmani
JGJoaquin Vega Gonzales-Portillo
Joaquin Vega Gonzales-Portillo
DGDaniel Gonzales-Portillo
Daniel Gonzales-Portillo
Cesar BorlonganCesar Borlongan
Cesar Borlongan
Ischemic brain injury represents a major cause of death worldwide with limited treatment options with a narrow therapeutic window. Accordingly, novel treatments that extend the treatment from the early neuroprotective stage to the late regenerative phase may accommodate a much larger number of stroke patients. To this end, stem cell-based regenerative therapies may address this unmet clinical need. Several stem cell therapies have been tested as potentially exhibiting the capacity to regenerate the stroke brain. Based on the long track record and safety profile of transplantable stem cells for hematologic diseases, bone marrow-derived mesenchymal stromal cells or mesenchymal stromal cells have been widely tested in stroke animal models and have reached clinical trials. However, despite the translational promise of MSCs, probing cell function remains to be fully elucidated. Recognizing the multi-pronged cell death and survival processes that accompany stroke, here we review the literature on MSC definition, characterization, and mechanism of action in an effort to gain a better understanding towards optimizing its applications and functional outcomes in stroke.